Conflict of interest: Nothing to declare.
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study
Article first published online: 25 NOV 2013
© 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 6, pages 982–986, June 2014
How to Cite
Weiss, B., Widemann, B. C., Wolters, P., Dombi, E., Vinks, A. A., Cantor, A., Korf, B., Perentesis, J., Gutmann, D. H., Schorry, E., Packer, R. and Fisher, M. J. (2014), Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study. Pediatr. Blood Cancer, 61: 982–986. doi: 10.1002/pbc.24873
- Issue published online: 16 APR 2014
- Article first published online: 25 NOV 2013
- Manuscript Accepted: 31 OCT 2013
- Manuscript Received: 9 SEP 2013
- Neurofibromatosis Clinical Trials Award for FY2007. Grant Number: W81XWH-05-1-0615
- clinical trials;
- new agents;
Patients with Neurofibromatosis Type 1 (NF1) have an increased risk of developing tumors of the central and peripheral nervous system, including plexiform neurofibromas (PN), which are benign nerve sheath tumors that are among the most debilitating complications of NF1. There are no standard treatment options for PN other than surgery, which is often difficult due to the extensive growth and invasion of surrounding tissues. Mammalian Target of Rapamcyin (mTOR) acts as a master switch of cellular catabolism and anabolism and controls protein translation, angiogenesis, cell motility, and proliferation. The NF1 tumor suppressor, neurofibromin, regulates the mTOR pathway activity. Sirolimus is a macrolide antibiotic that inhibits mTOR activity.
We conducted a 2-stratum phase II clinical trial. In stratum 2, we sought to determine whether the mTOR inhibitor sirolimus in subjects with NF1 results in objective radiographic responses in inoperable PNs in the absence of documented radiographic progression at trial entry.
No subjects had better than stable disease by the end of six courses. However, the children's self-report responses on health-related quality of life questionnaires indicated a significant improvement in the mean scores of the Emotional and School domains from baseline to 6 months of sirolimus.
This study efficiently documented that sirolimus does not cause shrinkage of non-progressive PNs, and thus should not be considered as a treatment option for these tumors. This study also supports the inclusion of patient-reported outcome measures in clinical trials to assess areas of benefit that are not addressed by the medical outcomes. Pediatr Blood Cancer 2014;61:982–986. © 2013 Wiley Periodicals, Inc.